Investors & Media

Investors & Media

Corporate Profile

At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Volume: 52 Week High: 52 Week Low:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Nov 16, 2020
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies In Rare for Life Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on November 19 SAN DIEGO , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Retrophin Inc.
Nov 12, 2020
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases SAN DIEGO , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited , a privately held,
Nov 11, 2020
SAN DIEGO , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and December: Jefferies 20 20   Virtual London Healthcare Conference Date: Wednesday, November 18,